If you’re looking for some investment options then you may want to look at the two listed below.

Here’s why analysts think these highly rated ASX 200 shares could be in the buy zone:

Goodman Group (ASX: GMG)

The first ASX 200 share to look at is Goodman Group. This integrated commercial and industrial property company owns a portfolio of in-demand properties with exposure to key growth markets such as ecommerce and logistics

The good news is that demand remains very strong and its development pipeline is filled to the brim with properties that look set to support its growth over the next decade.

In the meantime, Goodman recently upgraded its FY 2022 earnings guidance. Instead of 10% growth, the company now expects to deliver operating earnings per share growth of at least 15%.

The team at Citi still believe management is being conservative and could outperform this guidance. As a result, the broker recently retained its buy rating and lifted its price target to $27.50.

NEXTDC Ltd (ASX: NXT)

Another ASX 200 share for investors to look at is NEXTDC.

It provides scalable on-demand services to support outsourced data centre infrastructure and cloud connectivity from a collection of world class Tier III and Tier IV data centre facilities in key locations across Australia.

Thanks to the ongoing structural shift to the cloud, which is driving increasing demand for capacity in its data centres, NEXTDC appears well-placed to continue growing its earnings at a solid rate long into the future.

The team at Goldman Sachs expects this to be the case and is forecasting strong earnings growth over the coming years. The broker has pencilled in operating earnings growth of ~20% per annum through to at least FY 2024.

Goldman has a buy rating and $14.40 price target on the company’s shares

The post Analysts rate these ASX 200 shares as buys appeared first on The Motley Fool Australia.

More reading

• 10 ASX shares to buy in 2022
• Here’s why the Goodman Group (ASX: GMG) share price just hit an all-time high
• ASX shares to buy for the Omicron COVID outbreak
• 2 high-growth ASX shares profiting from the e-commerce boom
• Why these ASX 200 shares could be strong buys

Motley Fool contributor James Mickleboro owns shares of NEXTDC Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3pqjdN1

If you’re interested in adding some small caps to your portfolio, then you may want to check out the ones listed below.

These small cap shares are rated highly by analysts and have been given buy ratings recently. Here’s what you need to know about them:

Australian Clinical Labs Ltd (ASX: ACL)

Australian Clinical Labs could be a small cap share to buy. It is a leading Australian private provider of pathology services through 86 NATA accredited laboratories.

From these sites, the company performs a diverse range of pathology tests each year for a range of clients. These include doctors, specialists, patients, hospitals and corporate clients.

Outside the current increased demand for its services from COVID-19 testing, Goldman Sachs believes Australian Clinical Labs is well-placed for growth over the long term. This is due to demographic volume drivers, the prevalence of chronic diseases, and the growing trend for doctors to use pathology services to recognise, prevent or treat diseases earlier.

Goldman Sachs currently has a buy rating and $5.90 price target on the company’s shares. This compares to the most recent Australian Clinical Labs share price of $4.34.

Booktopia Group Ltd (ASX: BKG)

Booktopia could be another small cap ASX share to buy. It is an online book retailer which has been growing at a very strong rate in recent years. For example, in FY 2021, Booktopia reported a 26% increase in shipments to 8.2 million units and a 19% lift in active customers to 1.8 million. This underpinned very strong revenue growth again.

The good news is that with the shift to online shopping continuing and its new distribution centre able to ship more books that ever before, the future looks bright for Booktopia.

Analysts at Morgans are very positive on the company’s outlook. They believe Booktopia is well-placed to win market share and continue its growth.

Morgans currently has an add rating and $3.72 price target on its shares. This compares to the most recent Booktopia share price of $1.99.

The post Analysts are tipping huge gains for these small cap ASX shares appeared first on The Motley Fool Australia.

More reading

• 2 exciting small cap ASX shares named as buys
• 2 ASX healthcare shares rated as buys

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Booktopia Group Limited. The Motley Fool Australia has recommended Australian Clinical Labs Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3dyO1G5

ASX growth shares increasing in size quickly could be contenders for an investor’s portfolio.

There is growing volatility in the ASX share market. This may open up some better value opportunities for people to find.

Share prices regularly change, but lower prices give the chance getting exposure to quality companies at the best prices.

Here are two of them:

Doctor Care Anywhere Group PLC (ASX: DOC)

Doctor Care Anywhere is a UK-based telehealth company that is committed to delivering the best possible patient experience and clinical care through digitally enabled, joined up, evidence-based pathways on its platform. It has relationships with health insurers, healthcare providers and corporate customers to connect with a range of telehealth services.

It also recently completed the acquisition of Australian telehealth and tele-mental provider GP2U Telehealth. This gives the business another avenue for growth and geographical diversification. The ASX growth share has also entered the self-pay market in the Republic of Ireland through its channel partner Boots.

It’s expecting to report 2021 revenue growth of at least 100% compared to FY20, excluding the acquisition.

The three months to 30 September 2021 saw growth with a number of metrics. Quarter on quarter revenue growth was 21.6% to AU$10.7 million. Consultations grew by 30.6% to 116,800 with over 65% of consultations delivered to returning patients.

Activated lives reached 603,200 during the quarter – up 8% quarter on quarter. An activated life is the total number of people who have signed up for Doctor Care Anywhere’s service and entered their personal details.

Volpara Health Technologies Ltd (ASX: VHT)

Volpara describes itself as a health technology software company with an integrated platform which assists in the delivery of personalised breast care.

The ASX growth share grew its subscription revenue by 35% to NZ$11.8 million in the first half of FY22. Its revenue comes with a very high gross profit margin of 91.4%.

Its market share of women who have at least one Volpara product used on their image is around 34%.

Volpara says that its strategic commercial partnerships will help it achieve greater reach in not only genetic testing for breast cancer but expansion into the US lung cancer market where AI and software offer the prospect of saving many more lives.

It has partnered with a number of different organisations, including in lung, with RevealDx, Riverain Technologies, Natera and Invitae.

The company has a number of areas of focus for growth such as expanding the electronic health record (EHR) sales channel. It’s also working on building its data platform in a key effort to change from screening for detection to prevention.

It’s expecting to reach revenue of between NZ$25 million to NZ$26 million in this financial year.

Volpara management said the next few months is going to be “incredibly busy and exciting” as it heads to Chicago for the large radiology conference RSNA. The third and fourth quarters of the year are traditionally the biggest quarters for the business.

The post 2 fast growth ASX shares that could be buys in December 2021 appeared first on The Motley Fool Australia.

More reading

• Best-ever result: Volpara Health (ASX:VHT) share price jumps on half-year update
• Have money to invest? Here are 2 ASX shares that could be potential buys
• 3 exciting small cap ASX shares to watch
• 2 ASX shares that may be too good to ignore
• 2 ASX healthcare shares rated as buys

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Doctor Care Anywhere Group PLC and VOLPARA FPO NZ. The Motley Fool Australia owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool Australia has recommended Doctor Care Anywhere Group PLC. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3GfSBFw

If you’re wanting to add some ASX dividend shares to your portfolio, then it could be worth considering Telstra Corporation Ltd (ASX: TLS) shares.

Why could Telstra be a dividend share to buy?

Telstra could be a dividend share to buy due to its outlook being the best it has been in over a decade. This is being underpinned by the successful execution of its transformative T22 strategy and the growth targets included in its new T25 strategy.

In respect to the latter, Telstra is aiming for sustained growth and value by targeting mid-single digit underlying EBITDA and high-teens underlying earnings per share compound annual growth rates (CAGR) from FY 2021 to FY 2025.

Telstra’s CEO, Andrew Penn, commented: “T22 has been one of the largest, fastest and most ambitious transformations of a telco globally and today we are a vastly different company.”

“This means we are poised for growth as our society and economy increasingly digitises and we all work, study, transact and get our entertainment online. These fundamental shifts, together with T25, will underpin our future growth and shareholder value,” he added.

The response

These plans went down well with analysts, and particularly the team at Goldman Sachs. The broker believes Telstra is well-placed to grow its dividend in the coming years and is forecasting its first increase in almost a decade.

Goldman has pencilled in fully franked dividends per share of 16 cents for FY 2022 and FY 2023, before an increase to 18 cents in FY 2024 and then 19 cents in FY 2025.

Based on the current Telstra share price of $4.02, this implies yields of 4%, 4.5%, and then 4.7%, respectively.

Goldman also sees upside potential for the company’s shares. The broker has a price target of $4.40, which suggests the Telstra share price could rise almost 10% from current levels.

The post Hold the phone! Why Telstra (ASX:TLS) could be a dividend share to buy appeared first on The Motley Fool Australia.

More reading

• These 3 ASX 200 shares are topping the volume charts this Friday
• The Telstra (ASX:TLS) share price keeps rising. What happened in November?
• These 3 ASX 200 shares are topping the volume charts on Thursday
• These 3 ASX 200 shares are topping the volume charts this Wednesday
• Will its energy expansion drive the Telstra (ASX:TLS) share price to new heights?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Telstra Corporation Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/31qCYMv